On this episode of Longevity by Design, Dr. Gil Blander sits down with Dr. Karl Pfleger, aging biotechnology investor and creator of AgingBiotech.info, to dissect the rapidly evolving field of aging therapeutics. Karl breaks down the sector into two main categories: interventions that slow aging rates versus rejuvenation strategies that repair accumulated damage.

Karl highlights the most promising areas in his investment portfolio, including senolytics for clearing senescent cells and epigenetic reprogramming technologies. He explains why current aging clocks aren't ready for clinical use and discusses the limitations of popular interventions like GLP-1 drugs and fasting protocols. The conversation reveals that 14 Phase 3 clinical trials are currently testing core aging therapeutics.

The discussion covers recent FDA approvals for ATTR treatments and stem cell therapies, signaling the field's maturation. Karl emphasizes that meaningful life extension requires a "divide and conquer" strategy, targeting multiple aging mechanisms simultaneously rather than relying on single interventions. Despite exciting therapeutic developments, he maintains that optimizing diet, exercise, and sleep remains the most impactful strategy for extending healthspan today.

Guest-at-a-Glance

💡 Name: Dr. Karl Pfleger

💡 What they do: Angel investor, philanthropist, and advocate in aging and longevity biotechnology

💡 Institution(s): Creator and maintainer of AgingBiotech.info (comprehensive public database of 400+ aging companies)

💡 Noteworthy: Exclusively invests in aging/longevity sector with 15+ portfolio companies targeting damage repair approaches

💡 Where to find them: LinkedIn | AgingBiotech.info | X (Twitter)

Episode highlights:

00:00:00 Introduction to GLP-1 Drugs and Their Impact
00:00:56 Meet Dr. Karl Pfleger: A Pioneer in Aging and Longevity
00:02:50 Karl Pfleger's Journey from Tech to Aging Biology
00:05:18 The Current State of Longevity Biotech
00:09:47 Exciting Developments in Rejuvenation Biotechnology
00:24:17 Aging Biotech Info: A Comprehensive Resource
00:31:59 Future Plans for Aging Biotech Info
00:36:51 The Obesity Revolution: GLP-1 Receptor Agonists
00:40:29 Global Obesity Rates and GLP-1 Drugs
00:40:43 Potential Benefits and Limitations of GLP-1 Drugs
00:42:13 Muscle Atrophy and Side Effects of GLP-1 Drugs
00:44:12 Emerging Muscle Aging Treatments
00:46:10 Biotech Companies and Obesity Programs
00:46:53 Public vs. Private Biotech Companies
00:49:12 Fasting and Calorie Restriction
00:55:20 Blood Transfusions and Parabiosis
00:58:09 Metformin and N-of-1 Experiments
00:59:13 Comprehensive Aging Interventions
01:03:54 Diagnostics and Aging Clocks
01:13:49 Future of Aging Interventions
01:16:07 Top Tips for Health and Longevity

We Appreciate You!
As a token of our gratitude, we’re excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcast

For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

Karl Pfleger Explains the Aging Biotech Explosion

Longevity by Design